Shark Cartilage Monograph

References

• Riviere M, Alaoui-Jamali M, Falardeau P, et al. Neovastat(r): an inhibitor of angiogenesis with anti-cancer activity. Proceedings of the American Association for Cancer Research 1998; 39: 46
   Google Scholar
• Riviere M, Falardeau P, Latreille J, et al. Phase I/II lung cancer clinical trial results with AE-941 (Neovastat(r)) an inhibitor of angiogenesis. Clin Invest Med (supplement) 1998; 14
   Google Scholar
• Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975; 141(2)427–439
   PubMed Web of Science ®Google Scholar
• Talks K L, Harris A L. Current status of antiangiogenic factors. Br J Haematol 2000; 109(3)477–489
   PubMed Web of Science ®Google Scholar
• Leitner S P, Rothkopf M M, Haverstick D D, et al. Two phase II studies of oral dry shark cartilage powder (SCP) in patients with either metastatic breast or prostate cancer refractory to standard treatment. American Society of Clinical Oncology 1998; 17: A290
   Google Scholar
• Holt S. Shark cartilage and neutraceutical update. Alt Comp Ther 1995; 1: B414–416
   Google Scholar
• Lane I W, Contreras E. High rate of bioactivity (reduction in gross tumor size) observed in advance cancer patients treated with shark cartilage material. J Naturopath Mod 1992; 3(1)86–88
   Google Scholar
• Miller D R, Anderson G T, Stark J J, Granick J L, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998; 16(11)3649–3655
   PubMed Web of Science ®Google Scholar
• Riviere M, Latreille J, Falardeau P. AE-941 (Neovastat(r)), an inhibitor of angiogenesis: phase I/II cancer clinical trial results. Cancer Invest 1999; 17(suppl 1)16–17
   Google Scholar
• Milner M. A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint diseases. Amer Chiropractor 1999; 21: 40–42
   Google Scholar
• Hunt T J, Connelly J F. Shark cartilage for cancer treatment. Am J Health Syst Pharm 1995; 52(16)1756, 1760
   PubMed Web of Science ®Google Scholar
• Wilson J L. Topical shark cartilage subdues psoriasis. Altern Comp Ther 2001; 6: 291
   Google Scholar
• Menendez-Lopez J R, Rodriguez Fernandez-Britto JE, Lane I W. Previous Human Experience-Cuban Clinical Trials, http://www.lanelabs.com(1992 unpublished data, written by manufacturer, posted on manufacturer's website)
   Google Scholar
• Dupont E, Savard R E, Jourdain C, Juneau C, Thibodeau A, Ross N, et al. Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 1998; 2(3)146–152
   PubMedGoogle Scholar
• Coppes M J, Anderson R A, Egeler R M, Wolff J E. Alternative therapies for the treatment of childhood cancer. N Engl J Med 1998; 339(12)846–847
   PubMed Web of Science ®Google Scholar
• Rosenbluth R, Jennis A, Cantwell S, et al. Oral shark cartilage in the treatment of patients with advanced primary brain tumors. A phase II pilot study (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1999; 18: A554
   Google Scholar
• Saad F, Klotz L, Babaian R, Lacombe L, Champagne P, Dupont E. Phase I/II trial on AE-941 (Neovastat(r)) in patients with metastatic refractory prostate cancer (abstract presentation). Canadian Urological Association Annual Meeting. June, 24–272001
   Google Scholar
• Ashar B, Vargo E. Shark cartilage-induced hepatitis. Ann Intern Med 1996; 125(9)780–781
   PubMed Web of Science ®Google Scholar
• Evans W K, Latreille J, Batist G, et al. AE-941, an inhibitor of angiogenesis: rational for development in combination with induction chemotherapy/radiotherapy in-patients with non-small-cell lung cancer (NSCLC). Proffered Papers 1999; 250
   Google Scholar
• Corral L G, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999; 58(suppl 1)I107–I113
   PubMedGoogle Scholar
• Jamali M A, Riviere M, Falardeau P, et al. Effect of AE-941 (Neovastat(r)), an angiogenesis inhibitor, in the Lewis lung carcinoma metastatic model, efficacy, toxic-ity prevention and survival. Clin Invest Med 1998; 16
   Google Scholar
• Moses M A, Wiederschain D, Wu I, Fernandez C A, Ghazizadeh V, Lane W S, et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 1999; 96(6)2645–2650
   PubMed Web of Science ®Google Scholar
• Moller H J, Moller-Pedersen T, Damsgaard T E, Poulsen J H. Demonstration of immunogenic keratan sulphate in commercial chondroitin 6-sulphate from shark cartilage. Implications for ELISA assays. Clin Chim Acta 1995; 236(2)195–204
   PubMed Web of Science ®Google Scholar
• Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983; 221(4616)1185–1187
   PubMed Web of Science ®Google Scholar
• Moses M A, Sudhalter J, Langer R. Identification of an inhibitor of neo-vascularization from cartilage. Science 1990; 248(4961)1408–1410
   PubMed Web of Science ®Google Scholar
• Kuettner K E, Pauli B U. Inhibition of neovascularization by a cartilage factor. Ciba Found Symp 1983; 100: 163–173
   PubMedGoogle Scholar
• Langer R, Brem H, Falterman K, Klein M, Folkman J. Isolations of a cartilage factor that inhibits tumor neovascularization. Science 1976; 193(4247)70–72
   PubMed Web of Science ®Google Scholar
• McGuire T R, Kazakoff P W, Hoie E B, Fienhold M A. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy 1996; 16(2)237–244
   PubMed Web of Science ®Google Scholar
• Oikawa T, Ashino-Fuse H, Shimamura M, Koide U, Iwaguchi T. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 1990; 51(3)181–186
   PubMed Web of Science ®Google Scholar
• Sheu J R, Fu C C, Tsai M L, Chung W J. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on antiangiogenesis and anti-tumor activities. Anticancer Res 1998; 18(6A)4435–4441
   PubMed Web of Science ®Google Scholar
• Chen J S, Chang C M, Wu J C, Wang S M. Shark cartilage extract interferes with cell adhesion and induces reorganization of focal adhesions in cultured endothelial cells. J Cell Biochem 2000; 78(3)417–428
   PubMed Web of Science ®Google Scholar
• Moses M A. A cartilage-derived inhibitor of neovascularization and metal-loproteinases. Clin Exp Rheumatol 1993; 11(Suppl 8)67–S69
   PubMedGoogle Scholar
• Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Beliveau R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001; 21(1A)145–155
   PubMed Web of Science ®Google Scholar
• Berbari P, Thibodeau A, Germain L, Saint-Cyr M, Gaudreau P, Elkhouri S, et al. Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. J Surg Res 1999; 87(1)108–113
   PubMed Web of Science ®Google Scholar
• Neame P J, Young C N, Treep J T. Primary structure of a protein isolated from reef shark (Carcharhinus springeri) cartilage that is similar to the mammalian C-type lectin homolog, tetranectin. Protein Sci 1992; 1(1)161–168
   PubMed Web of Science ®Google Scholar
• Koch A E. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000; 59(suppl 1)i65–i71
   PubMedGoogle Scholar
• Zhuang L, Wang B, Shivji G, et al. AE-941, a novel inhibitor of angiogenesis has significant anti-inflammatory effect on contact hypersensitivity. Journal of Investigative Dermatology 1997; 108(4)633
   Google Scholar
• Gomes E M, Souto P R, Felzenszwalb I. Shark-cartilage containing preparation protects cells against hydrogen peroxide induced damage and mutagenesis. Mutat Res 1996; 367(4)204–208
   PubMedGoogle Scholar
• Felzenszwalb I, Pelielo de Mattos J C, Bernardo-Filho M, Caldeira-de-Araujo A. Shark cartilage-containing preparation: protection against reactive oxygen species. Food Chem Toxicol 1998; 36(12)1079–1084
   PubMed Web of Science ®Google Scholar
• Prudden J F. Cartilage as Therapy. Adjuvant Nutrition in Cancer Treatment Symposium, Tampa, Florida, September, 27–301995
   Google Scholar
• Lane W, Milner M. A comparison of shark cartilage and bovine cartilage. Townsend Letter 1996; 153: 40–42
   Google Scholar
• Mathews J. Media feeds frenzy over shark cartilage as cancer treatment. J Natl Cancer Inst 1993; 85(15)1190–1191
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA takes action against firm marketing unap-proved drugs. December 10, 1999, FDA talk paper
   Google Scholar
• Langer R, Conn H, Vacanti J, et al. Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proceedings of the National Academy of Sciences of the United States of America 1980; 1: 77
   Google Scholar
• Davis P F, He Y, Furneaux R H, Johnston P S, Ruger B M, Slim G C. Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc Res 1997; 54(2)178–182
   PubMed Web of Science ®Google Scholar
• Cataldi J, Osborne D. Effects of shark cartilage on mammary tumor neovas-cularization in vivo and cell proliferation in vitro (meeting abstract). FASEB Journal 1995; 9(3)A135
   Google Scholar
• Gonzalez R P, Soares F S, Farias R F, Pessoa C, Leyva A, Barros Viana G S, et al. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea. Biol Pharm Bull 2001; 24(2)151–154
   PubMed Web of Science ®Google Scholar
• Anonymous. Angiostatic and antitumoral activity of AE-941 (Neovastat(r)), a molecular fraction derived from shark cartilage (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1997; 38: A1530
   Google Scholar
• Barber R, Delahunt B, Grebe S K, Davis P F, Thornton A, Slim G C. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. Anticancer Res 2001; 21(2A)1065–1069
   PubMed Web of Science ®Google Scholar
• Shimizu-Suganuma M, Mwanatambwe M, Iida K, et al. Effect of shark cartilage on tumor growth and survival time in vivo (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1999; 18: A1760
   Google Scholar
• Horsman M R, Alsner J, Overgaard J. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol 1998; 37(5)441–445
   PubMed Web of Science ®Google Scholar
• Morris G M, Coderre J A, Micca P L, Lombardo D T, Hopewell J W. Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol 2000; 73(868)429–434
   PubMed Web of Science ®Google Scholar
• Renckens C N, van Dam F S. [The national cancer fund (Koningin Wilhelmina Fonds) and the Houtsmuller-therapy for cancer]. Ned Tijdschr Geneeskd 1999; 143(27)1431–1433
   PubMedGoogle Scholar
• Aeterna Laboratories Inc. Phase II study of AE-941 (Neovastat^(r); Shark Cartilage) in patients with early relapse or refractory multiple myeloma, http://www.clinicaltrials.govInformation Contact Number 1–888–349–3232
   Google Scholar
• National Cancer Institute. Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without shark cartilage extract in treating patients who have stage III non-small cell lung cancer that cannot be removed by surgery, http://www.clinicaltrials.govInformation Contact Number 715–387–5134
   Google Scholar
• Aeterna Laboratories Inc. Phase III randomized study of AE-941 (Neovastat^(r); Shark Cartilage Extract) in patients with metastatic renal cell carcinoma refractory to immunotherapy, http://www.clinicaltrials.govInformation Contact Number 1–888–349–3232
   Google Scholar
• Escudier B, Patenaude F, Bukowski R, et al. Rationale for a phase III clinical trial with AE-941 (Neovastat(r) (R)) in metastatic renal cell carcinoma patients refractory to immunotherapy. Annals of Oncology 2000; 11(suppl 4)143–144
   Google Scholar
• Saunder D N. Angiogenesis antagonist as treatment for psoriasis: Phase I clinical trial results with AE-941. American Academy of Dermatology Conference, New Orleans, Louisiana, March, 19–241999
   Google Scholar
• Goldman E. Shark cartilage extract tried as a novel psoriasis treatment. Skin All News 1998; 29(12)14
   Google Scholar
• Turcotte P. Phase I dose escalation study of AE-941, an antiangiogenic agent, in age-related macular degeneration patient. Retina Society Conference, Hawaii, December, 21999
   Google Scholar
• Fontenele J B, Viana G S, Xavier-Filho J, de Alencar J W. Antiinflammatory and analgesic activity of a water-soluble fraction from shark cartilage. Braz J Med Biol Res 1996; 29(5)643–646
   PubMed Web of Science ®Google Scholar
• Fontenele J B, Araujo G B, de Alencar J W, Viana G S. The analgesic and antiinflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent. Biol Pharm Bull 1997; 20(11)1151–1154
   PubMed Web of Science ®Google Scholar